RT Journal Article
SR Electronic
T1 Non-contrast-Enhanced Functional Lung MRI to evaluate treatment response of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: a pilot study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.03.23286576
DO 10.1101/2023.03.03.23286576
A1 Benlala, Ilyes
A1 Klaar, Rabea
A1 Gaass, Thomas
A1 Macey, Julie
A1 Bui, Stéphanie
A1 Berger, Patrick
A1 Laurent, François
A1 Dournes, Gael
A1 Dinkel, Julien
YR 2023
UL http://medrxiv.org/content/early/2023/03/07/2023.03.03.23286576.abstract
AB Background Allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) patients is associated with severe lung damage and requires specific therapeutic management. Repeated imaging is recommended to both diagnose and follow-up the response to treatment of ABPA in CF.Purpose To evaluate whether Fourier decomposition (FD) functional lung MRI can detect the response to treatment of ABPA in CF patients.Study type Retrospective longitudinal.Population A total of 12 CF patients.Field strength/sequence 2D balanced steady-state free precession (bSSFP) sequence with Fourier decomposition (FD) at 1.5T scanner.Assessment Ventilation weighted (V) and perfusion weighted (Q) maps were obtained after FD processing of the 2D coronal bSSFP time resolved images before and after treatment of ABPA. Defects extent was assessed on the functional maps using a visual semi quantitative score. Mean and coefficient of variation (cv) of the ventilation signal intensity (VSI) and the perfusion signal intensity (QSI) were calculated. Measurements were performed independently by two readers and averaged. The reproducibility of the measurements was also assessed. Pulmonary function tests (PFTs) were performed as markers of the airflow limitation severity.Statistical tests Comparisons of medians were assessed using paired Wilcoxon test. Reproducibility was assessed using the intraclass correlation coefficient (ICC). Correlations were assessed using Spearman test. A p value <0.05 was considered as significant.Results Defects extent on both V and Q maps showed a significant reduction after ABPA treatment (p<0.01). VSI_mean was significantly increased after treatment (p<0.01). Visual analyses reproducibility showed an ICC >0.93. ICC of the quantitative measurements was almost perfect (>0.99). VSI_cv and QSI_cv variations correlated inversely with the variation of obstructive parameters of PFTs (rho = -0.68, p=0.01).Data conclusion Non-contrast enhanced FD lung MRI appears to be able to reproducibly assess response to treatment of ABPA in CF patients and correlates with PFTs’ obstructive parameters.Competing Interest StatementF. Laurent reports personal fees and non-financial support from Chiesi, Boehringer, AstraZeneca, Bayer, Gilead and GSK, outside the submitted work; P. Berger reports personal fees and non-financial support from AstraZeneca, GSK, Novartis, Chiesi and Boehringer, and personal fees and non-financial support from Menarini and Sanofi, outside the submitted work.Funding StatementIlyes Benlala received academic funding from la Fondation du Souffle (Laureat 2021), la Fondation Bordeaux Universite-Fonds Delorme Broussin and IdEx Bordeaux LMU-Bordeaux Research Cooperation ProgramAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of University Hospital of Bordeaux gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors